We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...

Select your location to view local American Lung Association events and news near you.

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and the broader label. The company has estimated that among people with COPD who ...

AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

The COPD therapeutics market presents opportunities in integrated care and digital advancements. Rising disease prevalence ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

Quitting smoking and avoiding vaping may be crucial steps in managing COPD, as these habits expose your lungs to irritants that cause further damage. Quitting may slow the disease’s progression and ...

Just how common is COPD? And just how disheartening and confusing can a diagnosis be? These are questions our Senior Contributor Ted Koppel has been grappling with for very many years, and very close ...

Cardiovascular diseases and diabetes are some of the most common coexisting conditions in COPD. Shared risk factors and overlapping physiological processes likely contribute to the high rate of ...

GlaxoSmithKline’s (GSK) Nucala (mepolizumab) has been approved by the MHRA to treat adults with uncontrolled chronic ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

COPD stands for chronic obstructive pulmonary disease. The condition causes lung inflammation that leads to airflow blockage and breathing problems. [1] “COPD encompasses both emphysema and chronic ...